Scarica l'app Stockscreener
8.92
1.55%
-0.14
Pre-mercato:
8.97
0.05
+0.56%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BCRX Giù?
Forum
Previsione
Biocryst Pharmaceuticals Inc Borsa (BCRX) Ultime notizie
BIOCRYST (BCRX) director Jill Milne granted RSUs and options in board compensation - Stock Titan
BioCryst (BCRX) director receives stock grants and options, updates trust holdings - Stock Titan
BioCryst (BCRX) director receives RSU and option grants under board plan - Stock Titan
BioCryst (BCRX) director Steven Frank awarded RSUs and stock options - Stock Titan
BioCryst (NASDAQ: BCRX) director awarded RSUs and stock options as compensation - Stock Titan
BioCryst (BCRX) director Vincent Milano receives stock and option grants - Stock Titan
BioCryst (BCRX) director receives stock units and options grants - Stock Titan
Biocryst (NASDAQ: BCRX) director receives stock units and options grant - Stock Titan
Biocryst (BCRX) grants Theresa Heggie RSUs and stock options as board pay - Stock Titan
BioCryst Pharmaceuticals: Management's Plans For Multibillion HAE Franchise Add Up (BCRX) - Seeking Alpha
Why Did BCRX Stock Surge Over 10% In After-Hours Trading Today? - Stocktwits
BioCryst Pharmaceuticals' New Clinical Data Demonstrated Reduced Hereditary Angioedema Attacks With Orladeyo Treatment - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
BioCryst (NASDAQ: BCRX) investors approve 7M-share stock incentive plan - Stock Titan
Sector Update: Healthcare Stocks Advance Pre-Bell Friday - Moomoo
BioCryst Advances HAE Treatments with New Clinical Data (BCRX) - GuruFocus
BioCryst highlights efficacy gains across hereditary angioedema portfolio - grafa.com
BioCryst presents new data on HAE therapies at EAACI meeting - Investing.com
BioCryst presents new data on HAE therapies at EAACI meeting By Investing.com - Investing.com Canada
Oral HAE drug reduces child attacks; new antibody data across patient subgroups - Stock Titan
Is BioCryst Pharmaceuticals, Inc. (BCRX) A Good Stock To Buy Now? - Yahoo Finance
BioCryst Pharmaceuticals Grants Stock Options and RSUs to New Employees - Quiver Quantitative
Nine new BioCryst hires receive stock options, RSUs as inducement - Stock Titan
How Biocryst Pharmaceuticals Inc. (BCRX) Affects Rotational Strategy Timing - Stock Traders Daily
Do BioCryst’s EAACI 2026 HAE Data Plans Subtly Recast the BCRX Long-Term Innovation Story? - Sahm
BioCryst Pharmaceuticals Backs ORLADEYO Outlook as Navenibart Trial Advances - MarketBeat
BCRX Technical Analysis | Trend, Signals & Chart Patterns | BIOCRYST PHARMACEUTICALS INC (NASDAQ:BCRX) - ChartMill
Earnings call transcript: BioCryst Q1 2026: EPS Miss, Revenue Beat - Investing.com
BCRX: ORLADEYO and navenibart drive rare disease growth, with key milestones and profitability ahead - TradingView
BIOCRYST (BCRX) Board Chair Vincent Milano receives stock grant as retainer pay - Stock Titan
BioCryst (BCRX) director awarded stock in lieu of cash retainer - Stock Titan
BioCryst (BCRX) director Jill C. Milne receives 1,262-share stock grant as board retainer - Stock Titan
Biocryst (BCRX) director takes share grant instead of cash fee - Stock Titan
BIOCRYST (BCRX) director Steven Frank granted 1,262 shares instead of $11,250 cash - Stock Titan
These 10 mid-cap U.S. healthcare companies rank among the market's most attractively valued stocks - Seeking Alpha
Could BioCryst (BCRX) HAE Data at EAACI Quietly Redefine Its Core Investment Story? - Sahm
(BCRX) and the Role of Price-Sensitive Allocations - Stock Traders Daily
A Look At BioCryst Pharmaceuticals (BCRX) Valuation As Mixed Returns Temper Its Rare Disease Upside Narrative - Sahm
New ORLADEYO HAE data in children, adults to debut in Istanbul - Stock Titan
BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting - GlobeNewswire
BioCryst Pharmaceuticals’ SWOT analysis: stock eyes growth from pediatric expansion - Investing.com Nigeria
These Analysts Revise Their Forecasts On BioCryst Pharma After Q1 Earnings - Sahm
BCRX Should I Buy - Intellectia AI
Insider Selling: Amy Mckee Sells 11,180 Shares of BioCryst Pharm - GuruFocus
BioCryst director Amy McKee sells $100,284 in company shares - Investing.com UK
BioCryst director Amy McKee sells $100,284 in company shares By Investing.com - Investing.com South Africa
Director at Biocryst (NASDAQ: BCRX) sells 11,180 shares at $8.97 - Stock Titan
Biocryst’s BCX-17725 as new approach for Netherton syndrome - BioWorld News
Netherton Syndrome Market Set to Expand During the Forecast Period (2026-2036) as Novel Therapies Enter Development Pipeline | DelveInsight - Yahoo Finance
2.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):